A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study

Abstract

We performed a phase II study of belinostat in patients with acute myeloid leukemia (AML). In this open label phase II study (NCT00357032), patients with relapsed/refractory AML, or newly diagnosed patients with AML over the age of 60, were eligible. Belinostat was administered intravenously (IV) at a dose of 1000 mg/m² daily on days 1–5 of a 21-day cycle until progression or unacceptable toxicity. The primary endpoint was complete response (CR) rate, with secondary endpoints of overall response rate (CR + partial response [PR]), time to treatment failure (TTF), overall survival and safety. Twelve eligible patients with AML were enrolled, of whom six had received at least one prior line of therapy. No CR or PR was seen. Four patients had stable disease for at least five cycles. Grade 3 non-hematological toxicities occurred in four patients. Belinostat as monotherapy has minimal single-agent effect in AML on this dosing schedule.

Keywords::

• Histone deacetylase inhibitor
• leukemia
• phase II

Acknowledgements

This study was supported in part by contract N01-CM- 2011-00038 from the National Cancer Institute (NCI) Cancer Therapy Evaluation Program to the University of California at Davis (D. R. Gandara, Principal Investigator [PI]). Additional support from NCI Cancer Center Support Grants P30 CA033572 (City of Hope, M. Friedman, PI), P30CA093373 (University of California at Davis, R. DeVere-White, PI) and P30CA047904 (University of Pittsburgh, N. Davidson, PI) is acknowledged.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.